Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 525

Results For "US"

8117 News Found

Thermo Fisher launches big foot cell sorter in India
News | January 25, 2023

Thermo Fisher launches big foot cell sorter in India

Cell sorting technology supports researchers advancing new therapies


CrisprBits develops CRISPR-based SARS-CoV2 test OmiCrisp
Biotech | January 25, 2023

CrisprBits develops CRISPR-based SARS-CoV2 test OmiCrisp

OmiCrisp has been developed with support from Centre for Cellular And Molecular Platforms C-CAMP-InDx Program


Fadnavis inaugurates 310-bed Medicover Hospitals in Navi Mumbai
Healthcare | January 25, 2023

Fadnavis inaugurates 310-bed Medicover Hospitals in Navi Mumbai

Medical Tourism will boost India’s economy


75% of asthma patients have worse symptoms during cold or flu
Healthcare | January 25, 2023

75% of asthma patients have worse symptoms during cold or flu

Asthma patients are more likely to have an asthma attack during winter


Glenmark launches AKYNZEO I.V. in India
News | January 24, 2023

Glenmark launches AKYNZEO I.V. in India

It is administered as a single infusion 30 minutes prior to the start of each chemotherapy cycle that helps prevent, both, acute and delayed phases of CINV


Marksans Pharma announces UK MHRA approval for Fluoxetine 20mg/5ml Oral Solution
News | January 24, 2023

Marksans Pharma announces UK MHRA approval for Fluoxetine 20mg/5ml Oral Solution

The product will be manufactured at the plant of Bell, Sons & Co. (Druggists) Ltd. located at Gifford House, Slaidburn Crescent, Southport, UK


Supriya Lifescience appoints Krishna Raghunathan as CFO
People | January 24, 2023

Supriya Lifescience appoints Krishna Raghunathan as CFO

He was previously associated with renowned companies such as Granules India Ltd, Dr. Reddy’s Laboratories ltd & Aptar Group


Syngene Q3FY23 revenue reaches Rs. 803 Cr; PAT reaches Rs. 110 Cr
News | January 24, 2023

Syngene Q3FY23 revenue reaches Rs. 803 Cr; PAT reaches Rs. 110 Cr

The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid


Gland Pharma’s Q3 FY23 revenue stood at Rs. 938 Cr with gross margin of 54%
News | January 24, 2023

Gland Pharma’s Q3 FY23 revenue stood at Rs. 938 Cr with gross margin of 54%

The company is adding new capabilities of Combi-line for Microsphere, additional Bag line and lyos for the Penem block in Pashamylaram facility in Hyderabad and will be earmarking capital for further building on its Biosimilar CDMO facility


Astellas announces hold lifted by FDA on Fortis clinical trial of AT845
Drug Approval | January 23, 2023

Astellas announces hold lifted by FDA on Fortis clinical trial of AT845

Astellas stands on the forefront of healthcare change to turn innovative science into value for patients